Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Quinn

Showing results (71-80 of 255) with videos related to

Pageof 26
Sort By:
Cancer Research|May 15, 1998
Granulosa cell tumors express erbB4 and are sensitive to the cytotoxic action of heregulin-beta2/PE40C Furger, R J Fiddes, D I Quinn, et al.
Clinical Advances in Hematology & Oncology : H&O|July 28, 2017
Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic diseaseSteven S Yu, Tanya B Dorff, Leslie K Ballas, et al.
Urologic Oncology|November 19, 2013
Effect of gender on outcomes following radical cystectomy for urothelial carcinoma of the bladder: a critical analysis of 1,994 patientsAnirban P Mitra, Eila C Skinner, Anne K Schuckman, et al.
World Journal of Urology|November 21, 2008
Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experienceTanya B Dorff, Denice Tsao-Wei, Gus Miranda, et al.
Clinical Advances in Hematology & Oncology : H&O|July 28, 2017
Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatmentSteven S Yu, Leslie K Ballas, Eila C Skinner, et al.
Cancer Medicine|March 27, 2025
A Phase I/IB, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab in Combination With Vorinostat in Patients With Advanced Prostate, Renal or Urothelial CarcinomaRoberto Pili, David I Quinn, Nabil Adra, et al.
Prostate Cancer and Prostatic Diseases|June 14, 2003
Downregulation of KAI1 mRNA in localised prostate cancer and its bony metastases does not correlate with p53 overexpressionP Jackson, K Ow, G Yardley, et al.
Expert Review of Anticancer Therapy|November 15, 2013
Sequencing therapy in advanced prostate cancer: focus on sipuleucel-TDavid I Quinn, Ulka Vaishampayan, Celestia S Higano, et al.
Clinical Genitourinary Cancer|August 23, 2017
Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC)Mitchell E Gross, Tanya B Dorff, David I Quinn, et al.
The Journal of Urology|January 7, 2022
Reply by AuthorsAnirban P Mitra, Jie Cai, Gus Miranda, et al.
Pageof 26

Showing results (71-80 of 255) with videos related to

Sort By:
Pageof 26
Cancer Research|May 15, 1998
Granulosa cell tumors express erbB4 and are sensitive to the cytotoxic action of heregulin-beta2/PE40C Furger, R J Fiddes, D I Quinn, et al.
Clinical Advances in Hematology & Oncology : H&O|July 28, 2017
Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic diseaseSteven S Yu, Tanya B Dorff, Leslie K Ballas, et al.
Urologic Oncology|November 19, 2013
Effect of gender on outcomes following radical cystectomy for urothelial carcinoma of the bladder: a critical analysis of 1,994 patientsAnirban P Mitra, Eila C Skinner, Anne K Schuckman, et al.
World Journal of Urology|November 21, 2008
Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experienceTanya B Dorff, Denice Tsao-Wei, Gus Miranda, et al.
Clinical Advances in Hematology & Oncology : H&O|July 28, 2017
Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatmentSteven S Yu, Leslie K Ballas, Eila C Skinner, et al.
Cancer Medicine|March 27, 2025
A Phase I/IB, Open Label, Dose Finding Study to Evaluate Safety, Pharmacodynamics and Efficacy of Pembrolizumab in Combination With Vorinostat in Patients With Advanced Prostate, Renal or Urothelial CarcinomaRoberto Pili, David I Quinn, Nabil Adra, et al.
Prostate Cancer and Prostatic Diseases|June 14, 2003
Downregulation of KAI1 mRNA in localised prostate cancer and its bony metastases does not correlate with p53 overexpressionP Jackson, K Ow, G Yardley, et al.
Expert Review of Anticancer Therapy|November 15, 2013
Sequencing therapy in advanced prostate cancer: focus on sipuleucel-TDavid I Quinn, Ulka Vaishampayan, Celestia S Higano, et al.
Clinical Genitourinary Cancer|August 23, 2017
Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC)Mitchell E Gross, Tanya B Dorff, David I Quinn, et al.
The Journal of Urology|January 7, 2022
Reply by AuthorsAnirban P Mitra, Jie Cai, Gus Miranda, et al.
Pageof 26